Clinical predictive value of serum angiogenic factor in patients with osteosarcoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4823-4826

  Chen, Zhe ^a,b   Chen, Qi Xin ^a   Hou, Zhao Yang ^b   Hu, Jiong ^b   Cao, Yan Guang ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenic facor; Microvessel density; Osteosarcoma

Indexed keywords

EID: 84874014854     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4823     Document Type: Article

References (24)

1. Balu S, Pirtea L, Gaje P, et al (2012). The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom J Morphol Embryol, 53, 479-83.
2. Dirkx AE, oude Egbrink MG, Castermans K, et al (2006). Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J, 20, 621-30.
3. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
4. Hlobilkova A, Ehrmann J, Knizetova P, et al (2009). Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma, 56, 284-90.
5. Kasuya K, Nagakawa Y, Suzuki M, et al (2011). Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med, 2, 1047-52.
6. Kim HS, Lim SJ, Park YK (2009). Anti-angiogenic factor endostatin in osteosarcoma. APMIS, 117, 716-23.
7. Lee JA, Ko Y, Kim DH, et al (2012). Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat, 44, 202-9.
8. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
9. Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pacific J Cancer Prev, 12, 487-90.
10. Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al(2011).
11. Malamitsi-Puchner A, Boutsikou T, Economou E, et al (2005). The role of the anti-angiogenic factor endostatin in intrauterine growth restriction. J Soc Gynecol Investig, 12, 195-7.
12. Nataraj NB, Salimath BP (2012). Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma. Cell Signal, 25, 277-94.
13. Oda Y, Yamamoto H, Tamiya S, et al (2006). CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol, 19, 738-45. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev, 12, 1717-22.
14. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev, 12, 1717-22.
15. Sunshine SB, Dallabrida SM, Durand E, et al (2012). Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A, 109, 11306-11.
16. Tan H, Mu G, Zhu W, et al (2011). Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. Biol Pharm Bull, 34, 545.
17. Tsubaki M, Yamazoe Y, Yanae M, et al (2011). Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. Cytokine, 54, 100-7.
18. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
19. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
20. Yang J, McNeish B, Butterfield C, et al (2012). Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J, Epub ahead of print.
21. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
22. Zhang G, Li M, Jin J, Bai Y (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.
23. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
24. Zheng MJ (2009). Endostatin derivative angiogenesis inhibitors. Chin Med J, 122, 1947-51.